drug-eluting coronary stent

drug-e·lut·ing cor·o·nar·y stent

(drŭg'ē-lūt'ing kōr'ŏ-nar-ē stent)
A widely used device with metal surfaces that are coated with a drug to prevent restenosis; used to maintain luminal patency; some study results suggest that when the drug wears off and leaves the bare metal exposed, there is a possibility of acute heart attack and sudden death.
Mentioned in ?
References in periodicals archive ?
DIRECT II is a prospective, randomized, multi-center clinical study comparing the safety and efficacy of the Svelte drug-eluting coronary stent-on-a-wire Integrated Delivery System and the Medtronic Resolute Integrity drug-eluting coronary stent in 159 patients undertaken in support of CE Mark certification of the Svelte IDS.
Svelte Medical Says Drug-Eluting Coronary Stent-on-a-Wire Demonstrates Sustained Clinical Results
About three-quarters underwent an elective stenting procedure, and slightly more than half received a drug-eluting coronary stent.
Registry fails to find adverse PPI-Clopidogrel interaction
When the analysis was confined to the 179 PCI patients (71%) who received a drug-eluting coronary stent, the results shifted slightly in favor of PCI.
Diabetic patients may fare as well from stents as from CABG
Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery.
Perioperative complications in patients with drug-eluting stents: a three-year audit at Geelong Hospital
"Incorporating Guidant's latest delivery technology promises to improve our current product line and give us entry into the next generation of drug-eluting coronary stent systems earlier than originally anticipated.
Cordis forms stent alliance with Guidant
The company said that Resolute Integrity Stent System features a novel drug-eluting coronary stent with superior deliverability - the ability of the device to traverse the patient's vasculature and reach the blockage in the heart artery.
Medtronic announces launch of Resolute Integrity Stent System
The company also received the FDA's nod for its second-generation Taxus Liberte drug-eluting coronary stent system.
Boston scientific gets good news from the FDA
has received regulatory approval from Health Canada's Therapeutic Products Directorate (TPD) for use of the Endeavor drug-eluting coronary stent (DES) system in the treatment of coronary artery disease.
MEDTRONIC'S NEW ENDEAVOR STENT APPROVED IN CANADA
Atlanta -- Patients with a drug-eluting coronary stent had a 4.9% rate of cardiac death or myocardial infarction during the first year after they stopped daily treatment with clopidogrel, more than three times the rate in patients with bare-metal stents in a study with 743 patients.
Stent thrombosis rises when clopidogrel stops
The review included 5,342 patients at Prairie Heart who received their first drug-eluting coronary stent during May 2003--December 2006.
Stent thrombosis rates increase over time
The TAXUS Liberte stent is currently the market-leading drug-eluting coronary stent system outside the U.S.
BOSTON SCIENTIFIC GETS CE MARK FOR TAXUS LIBERTE LONG STENT
Abbott Vascular's drug eluting stent program is comprised of two flagship investigational products: the XIENCE V Everolimus Eluting Coronary Stent System and the ZoMaxx(TM) Drug-Eluting Coronary Stent System.
ABBOTT ENROLLS FIRST PATIENT IN XIENCE STENT TRIAL

Medical browser ?
Full browser ?